Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews the use of sorafenib, a multikinase inhibitor, for treating certain carcinomas, noting that cutaneous toxicity during treatment may indicate successful antitumor activity; however, it reports no new clinical results.

This study identified five FDA-approved drugs—cepharantine, clofazimine, metergoline, imatinib, and efloxate—as potential candidates for repurposing to interfere with viral entry in COVID-19 treatment.

This study found that Golvatinib, Gliquidone, and Dihydroergotamine may inhibit the binding of SARS-CoV-2's Nsp1 protein to the host ribosomal subunit, suggesting potential as treatments against COVID-19 variants.

This study found that adjuvant sorafenib after hepatic resection improved overall survival in patients with intermediate and advanced hepatocellular carcinoma, compared to surgery only.

This study found that the CYP3A4 rs4646437 genotype was significantly associated with ALT elevation in Japanese patients undergoing asunaprevir plus daclatasvir therapy for chronic HCV infection, suggesting genotyping may help in monitoring patients safely.

This study highlights the approval of orforglipron under the FDA's National Priority Voucher program, emphasizing its significance as a convenient oral treatment option with beneficial effects on glycemic and lipid profiles for diabetes and obesity management.

In this study, peginterferon alfa-2b plus ribavirin therapy in hepatitis C patients was associated with serious adverse drug reactions in 20% of cases, highlighting differences from clinical trial findings.

This case report describes a patient with painful skin lesions during sorafenib treatment whose symptoms improved after receiving photodynamic therapy, suggesting it might help manage similar refractory skin toxicity cases.

This study observed that MIRV improved gastrointestinal symptoms and other quality of life measures in patients with platinum-resistant ovarian cancer compared to chemotherapy.

This report describes a case of alopecia totalis associated with lopinavir/ritonavir in an HIV-positive patient, which reversed after discontinuation of the drug.

In this study, a high daily dose of interferon alfa-2b administered initially six times a week for two weeks followed by thrice weekly for 12 weeks was most effective in sustaining normal ALT values in patients.

This study reports that sorafenib-associated facial acneiform eruption, mimicking chloracne, is a rare cutaneous adverse event which improved upon reducing or discontinuing the drug.

This review discusses fixed drug eruption (FDE) potentially linked to finasteride and emphasizes dermatologists' need to recognize its possible occurrence due to the drug's widespread use, but reports no new clinical results.

This study found that intermittent treatment with FTI lonafarnib and sulforaphane may be a promising therapeutic approach for children with Hutchinson-Gilford progeria syndrome, as it improved the cellular phenotype.

In this study, a 10-year-old girl developed vitiligo and psoriasis during IFN-alfa treatment for chronic hepatitis B, with neither condition improving after stopping the therapy.

In this study, sorafenib's common adverse events, like a hand-foot syndrome and diarrhea, were observed in distinct temporal and tissue distribution patterns, revealing new relationships among effects.

In this case report, a patient on low-dose sorafenib for hepatocellular carcinoma developed a rare and severe facial acneiform eruption without other skin side effects, which improved only minimally with topical treatment.

In this study, 97% of patients undergoing pegylated interferon alfa2a and ribavirin therapy for chronic hepatitis C experienced one or more skin-related side effects, with hair loss being the most common.

This abstract describes the initial success of intralesional cidofovir for SCC treatment and states that it has not shown systemic toxicity, but it does not report new clinical trial results.

This case study reports a unique and severe papulopustular eruption, likely induced by sorafenib treatment in a patient with metastatic renal cancer, which manifested as hyperkeratotic spicules and improved with cessation of the drug.

This study explored new molecular structures as potential COVID-19 treatments, identifying a compound called Hit15 that inhibited viral infection in lab settings and reduced inflammation markers in human neutrophils, suggesting further development is warranted.

This study found that the compound M50054 inhibits apoptosis by blocking caspase-3 activation and may improve chemotherapy-induced alopecia and hepatitis symptoms.

This case report documents a reversible instance of complete body hair loss (alopecia universalis) in a patient undergoing chronic hepatitis C treatment with pegylated interferon alpha-2b and ribavirin, with hair regrowth observed within three months after therapy completion.

This case study reports the first instance of irreversible alopecia universalis occurring during pegylated interferon-ribavirin therapy in a man with hepatitis C infection, without evidence of immunological or thyroid disorders.

This article discusses topical and intralesional cidofovir use for SCC and suggests a successful outcome in one case, with no systemic toxicity observed so far.

In this study, tebentafusp-tebn improved overall survival in patients with metastatic uveal melanoma compared to standard therapies, despite higher rates of significant adverse events.

This review summarizes 25 small molecule drugs with in vitro and in vivo data for COVID-19 treatment, highlighting their structural diversity and potential to guide future antiviral discovery.

This study reported two cases of alopecia universalis triggered by PEG-interferon and ribavirin therapy for chronic hepatitis C, with hair regrowth observed after therapy completion or withdrawal.

This study found that recombinant IFN α-2b injections in patients with acute post-transfusion hepatitis C can suppress viral RNA and lead to normalization of serum ALT, though long-term prevention of chronicity remains unclear.

This case report links sorafenib treatment in a 22-year-old man with relapsed acute myeloid leukemia to a rare instance of drug-induced pityriasis rubra pilaris-like eruption.